Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jay Ramchand

Showing results (11-20 of 52) with videos related to

Pageof 6
Sort By:
Heart (British Cardiac Society)|May 27, 2020
Advanced imaging for risk stratification of sudden death in hypertrophic cardiomyopathyJay Ramchand, Agostina M Fava, Michael Chetrit, et al.
BMJ Case Reports|May 19, 2016
Cardiac metastatic melanomaJay Ramchand, Geoffrey R Wong, Matias B Yudi, et al.
International Journal of Molecular Sciences|April 28, 2018
Kruppel-Like Factor 15 Is Critical for the Development of Left Ventricular HypertrophySheila K Patel, Jay Ramchand, Vincenzo Crocitti, et al.
Heart (British Cardiac Society)|January 18, 2020
Advanced imaging for risk stratification of sudden death in hypertrophic cardiomyopathyJay Ramchand, Agostina M Fava, Michael Chetrit, et al.
Quality of Life Research : an International Journal of Quality of Life Aspects of Treatment, Care and Rehabilitation|May 20, 2020
Mapping the Minnesota Living with Heart Failure Questionnaire (MLHFQ) onto the Assessment of Quality of Life 8D (AQoL-8D) utility scoresMax Catchpool, Jay Ramchand, David L Hare, et al.
Expert Opinion on Investigational Drugs|September 8, 2020
Mavacamten: a novel small molecule modulator of β-cardiac myosin for treatment of hypertrophic cardiomyopathyAlbree Tower-Rader, Jay Ramchand, Steve E Nissen, et al.
Heart (British Cardiac Society)|November 16, 2018
Further studies needed before using renin-angiotensin-aldosterone system blockade for atrial fibrillation prevention in hypertrophic cardiomyopathyJay Ramchand, Thalys Sampaio Rodrigues, Matias B Yudi, et al.
Plos One|June 14, 2018
Elevated plasma angiotensin converting enzyme 2 activity is an independent predictor of major adverse cardiac events in patients with obstructive coronary artery diseaseJay Ramchand, Sheila K Patel, Piyush M Srivastava, et al.
Current Cardiology Reports|July 2, 2020
Erdheim-Chester Disease: a Rare but Important Cause of Recurrent PericarditisJohnny Chahine, Jafar Alzubi, Hanan Alnajjar, et al.
BMC Nephrology|July 5, 2018
Left ventricular hypertrophy in experimental chronic kidney disease is associated with reduced expression of cardiac Kruppel-like factor 15Sheila K Patel, Elena Velkoska, Daniel Gayed, et al.
Pageof 6

Showing results (11-20 of 52) with videos related to

Sort By:
Pageof 6
Heart (British Cardiac Society)|May 27, 2020
Advanced imaging for risk stratification of sudden death in hypertrophic cardiomyopathyJay Ramchand, Agostina M Fava, Michael Chetrit, et al.
BMJ Case Reports|May 19, 2016
Cardiac metastatic melanomaJay Ramchand, Geoffrey R Wong, Matias B Yudi, et al.
International Journal of Molecular Sciences|April 28, 2018
Kruppel-Like Factor 15 Is Critical for the Development of Left Ventricular HypertrophySheila K Patel, Jay Ramchand, Vincenzo Crocitti, et al.
Heart (British Cardiac Society)|January 18, 2020
Advanced imaging for risk stratification of sudden death in hypertrophic cardiomyopathyJay Ramchand, Agostina M Fava, Michael Chetrit, et al.
Quality of Life Research : an International Journal of Quality of Life Aspects of Treatment, Care and Rehabilitation|May 20, 2020
Mapping the Minnesota Living with Heart Failure Questionnaire (MLHFQ) onto the Assessment of Quality of Life 8D (AQoL-8D) utility scoresMax Catchpool, Jay Ramchand, David L Hare, et al.
Expert Opinion on Investigational Drugs|September 8, 2020
Mavacamten: a novel small molecule modulator of β-cardiac myosin for treatment of hypertrophic cardiomyopathyAlbree Tower-Rader, Jay Ramchand, Steve E Nissen, et al.
Heart (British Cardiac Society)|November 16, 2018
Further studies needed before using renin-angiotensin-aldosterone system blockade for atrial fibrillation prevention in hypertrophic cardiomyopathyJay Ramchand, Thalys Sampaio Rodrigues, Matias B Yudi, et al.
Plos One|June 14, 2018
Elevated plasma angiotensin converting enzyme 2 activity is an independent predictor of major adverse cardiac events in patients with obstructive coronary artery diseaseJay Ramchand, Sheila K Patel, Piyush M Srivastava, et al.
Current Cardiology Reports|July 2, 2020
Erdheim-Chester Disease: a Rare but Important Cause of Recurrent PericarditisJohnny Chahine, Jafar Alzubi, Hanan Alnajjar, et al.
BMC Nephrology|July 5, 2018
Left ventricular hypertrophy in experimental chronic kidney disease is associated with reduced expression of cardiac Kruppel-like factor 15Sheila K Patel, Elena Velkoska, Daniel Gayed, et al.
Pageof 6